Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Transport:
To ask the Secretary of State for Transport, if she will make an assessment of the adequacy of the accessibility of the consultation entitled RVAR 2010 exemption: Chiltern Railways passenger information system, published on 3 December 2024.
Answered by Simon Lightwood - Parliamentary Under-Secretary (Department for Transport)
The Department for Transport considers the ‘RVAR 2010 exemption: Chiltern Railways passenger information system’ consultation to be accessible.
Rail vehicle accessibility public consultations are published on GOV.UK in a format known as HTML which is accessible by default and easier for most people to use. The consultation offers two mechanisms, email and post, for consultees to respond via.
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into lyme disease research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into reactive arthritis research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government investment into vitamin D deficiency disease research there was in 2023-24; and which public bodies provided that investment.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into fibromyalgia research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into osteomalacia research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into ankylosing spondylitis research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into stills disease research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government investment into multiple myeloma there was in 2023-24; and which public bodies provided that investment.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government investment into compression fracture research there was in 2023-24; and which public bodies provided that investment.
Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
rheumatoid arthritis | The total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577). | NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24. |
osteoarthritis | The total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs). | NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24. |
psoriatic arthritis | The total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK). | NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24. |
systemic lupus erythematosus | The total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608) | The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24. |
joint replacement | The total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC). | The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24. |
crystal arthropathy | UKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date. | The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24. |
osteoporosis | The total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC). | NIHR allocated £379,475 for research concerning osteoporosis in F/Y. |
compression fracture | UKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date. | NIHR has not funded any research concerning compression fracture during F/Y 2023-24. |
multiple myeloma | UKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to date | NIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24. |
vitamin D deficiency disease | The total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK). | NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24. |
osteomalacia | UKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24 |
Fibromyalgia | UKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date. | NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24. |
ankylosing spondylitis | UKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date. | NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24. |
stills disease | UKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date. | NIHR has not funded any research concerning stills disease during F/Y 2023-24. |
lyme disease | The total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC). | NIHR has not funded any research concerning lyme disease during F/Y 2023-24 |
reactive arthritis | UKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date. | The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24. |